Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Tataa Biocenter is partnering with Olink and Illumina to offer high performance proteomics with unprecedented throughput

Tataa Biocenter AB, a leading European provider of molecular analysis services with ISO 17025 accreditation, is launching Olink® EXPLORE 3072 proteome profiling service. This new platform offers exceedingly high performance with unprecedented throughput based on Illumina sequencing technology.Olink’s technology — Proximity Extension Assay (PEA) — uses pairs of antibodies with DNA tags that prime PCR when bound to the targeted protein. With Olink® EXPLORE 3072, next-generation sequencing is used to quantify each of 3072 protein targets. Tataa Biocenter  has more than

Metso Outotec launches a new mobile impact crusher to the Nordtrack range

Metso Outotec Corporation’s press release on March 9, 2022, at 9:00 a.m. EETMetso Outotec adds a new impact crusher to its Nordtrack[ ]mobile crushing and screening range, targeting especially smaller-sized applications and jobsites in the construction and demolition waste recycling segment. The Nordtrack™ I1011 mobile impactor has compact dimensions and a powerful, high-performance crusher, ideally suited for contractors and rental work. Equipped with a large hanging screen, it combines high crushing capacity with calibrated end product accuracy. The versatile Nordtrack I1011 crusher is

Orthex financial statements release 2021: Strong growth under increasingly challenging conditions

Orthex Corporation, Stock exchange release, 9 March 2022 at 9.00 a.m. EETThis release is a summary of Orthex Corporation’s financial statements release 2021. The complete report is attached to this release as a pdf-file. It is also available on Orthex’s website at https://investors.orthexgroup.com/. January–December 2021 in Brief · Invoiced sales increased by 16.3% and totalled EUR 90.6 million (77.9) · Net sales increased by 16.9% to EUR 88.7 million (75.9) · Adjusted EBITDA was EUR 14.8 million (17.1) · EBITA was EUR 9.4 million (12.3) and adjusted EBITA was EUR 11.0

The Board of SBB proposes that the AGM resolves on a contribution of SEK 50m for UNHCR's work in Ukraine. The contribution does not affect the ordinary dividend for SBB's ordinary shareholders.

Samhällsbyggnadsbolaget i Norden AB (“SBB”) already has a long-term collaboration with UNHCR, which is about ensuring that refugees have a roof over their heads. According to the UNHCR, even before the war in Ukraine, they are responsible for the needs of some 5.5 million refugees living in refugee camps and settlements. Own housing means protection, security, privacy, comfort and health. "We have a war in Europe and we must all do everything we can to contribute. UNHCR does a fantastic job of helping people affected by war. SBB has already previously contributed to UNHCR and via our

Q4 Report – 31 December 2021

Flexion produces record results: 52% growth in revenue, 63% growth in gross profit and 163% growth in EBITDAOctober 2021 to December 2021 performance · Total revenue increased by 52% to GBP 10.5m (GBP 6.9m)* · Gross profit increased by 63% to GBP 1.5m (GBP 0.9m) · Adjusted EBITDA[‡] increased by 163% to GBP 0.33m (GBP 0.13m) · Operating profit increased to GBP 0.63m (GBP 0.06m) · Earnings per share amounted to GBP 1.28 pence (GBP 0.13 pence) · Cash amounted to GBP 14.5m (GBP 12.4m) April 2021 to December 2021 performance · Total revenue increased by 46% to GBP 26.

Saab Australia Expansion Awarded Multi-Million Dollar Government Grant

Saab Australia will further secure its commitment to Australia with a multi-million dollar development expanding its national facility near Adelaide. This is part of Saab’s internationalisation strategy, focused in selected countries such as Australia, to become a multi-domestic company.The growing defence innovator has been awarded AUD$22.6m funding from the latest round of the Australian Government’s Modern Manufacturing Initiative. The grant will see the establishment of the nation’s first, state-of-the-art Sovereign Combat System Collaboration Centre as part of the construction of Saab’

Notice of extraordinary general meeting in SynAct Pharma AB

The shareholders in SynAct Pharma AB, Reg. No. 559058-4826 (“SynAct”), are hereby invited to the extraordinary general meeting to be held on Monday March 28, 2022.In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the board of directors has decided that the meeting will be held only by advance voting (postal vote) in accordance with temporary legislation. This means that the meeting will be conducted without the physical presence of shareholders, proxies or external parties and that shareholders' exercise of voting rights at the meeting can

Vicore strengthens rare lung disease pipeline with PAH indication

· Strong preclinical data shows that C21 reverses vascular remodelling · Proof-of-concept trial in pulmonary arterial hypertension ("PAH") planned to start late 2022 · Appointment of two new senior clinical advisors in PAHGothenburg, March 9, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the Angiotensin II type 2 receptor (AT2R), today announces plans to initiate a clinical trial with C21 in PAH. Pulmonary arterial hypertension (PAH) is a rare lung disease with huge unmet medical need where existing

UPM to suspend purchasing of wood in and from Russia and operations at its Chudovo plywood mill

(UPM, Helsinki, 9 March 2022 at 9:00 EET) – UPM will suspend purchasing of wood in and from Russia as well as the UPM Chudovo plywood mill operations for the time being. The company is preparing a mitigation plan accordingly. UPM also informed on 3 March 2022 that it will cease deliveries to Russia . The suspension will be implemented with due consideration of UPM’s local employees, customers and stakeholders as well as the legislation in Russia. UPM continues to honour its obligations towards

The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB

The Nomination Committee of SynAct Pharma AB (“SynAct”) has informed the company that the Nomination Committee proposes that Kerstin Hasselgren is elected as a new ordinary board member of SynAct for the period until the end of the next Annual General Meeting, together with the board members elected at the Annual General Meeting on 21 May 2021.Kerstin Hasselgren (born 1961) is currently CFO of Xspray Pharma AB listed on Nasdaq Stockholm. Kerstin Hasselgren has extensive experience from working in large public international companies such as VP Corporate Business Control at SSAB, CFO at

Flex LNG - Presentation at the DNB Energy & Shipping Conference March 2022

March 9, 2022 – Hamilton, Bermuda Flex LNG will attend at the DNB Energy & Shipping Conference in Oslo today. Please find attached the presentation to be used in investor relations meetings.  The presentation is also available on our website www.flexlng.com For further information, please contact:Mr. Knut Traaholt, Chief Financial Officer of Flex LNG Management ASTelephone: +47 23 11 40 00Email: ir@flexlng.com 

HANZA extends contract with Swisslog AS

HANZA Holding AB (publ), a leading provider of complete manufacturing solutions, has expanded the agreement with Swisslog AS to support their turnkey automated warehousing solution project in Mo i Rana, Norway. The order value is not disclosed but is expected to amount to lower double digits MSEK per year.The assignment includes the manufacture and delivery of a total of 86,000 steel cases to Mo i Rana. “We are really looking forward to deepening the cooperation with Swisslog AS, a company that fits well with HANZA’s business model says Veronica Svensson, Sales Director Scandinavia. A

Bravida awarded contract by NCC to carry out electrical and pipe installations, with an order value of SEK 82 million

Bravida has been assigned the task by NCC of carrying out all the electrical and pipe installations for the new MIMO office building in Mölndal, Gothenburg. The building involves 40,000 square metres of new construction spread over 17 floors.MIMO is located in the centre of Mölndal, close to all the services needed for everyday life. MIMO will provide, for example, the exercise facilities, healthy food options, lighting, materials, colour, ventilation and other factors that make people feel good at their workplace. The building is certified to BREEAM level Excellent, which means it is of

Skanska buys land in Stockholm, Sweden, for about SEK 340M

Skanska has acquired approximately 6,600 square meters of land in Hammarby Sjöstad, Stockholm, Sweden from the City of Stockholm. The total investment amounts to about SEK 340M.On the land plot, Skanska plans to develop two more office buildings within the framework of the Sthlm New development project, within which five office buildings have previously been developed or are under development. The building right covers approximately 31,000 square meters. The area is one of Stockholm's fastest growing workplace areas with high sustainability ambitions. The ongoing expansion of Stockholm's

Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting

Oslo, Norway, 9 March 2022 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces that an E-poster regarding Alpha37, entitled “Targeted alpha therapy with [212]Pb-NNV003 in treatment of NHL”, will be presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting held 8-13 April in New Orleans, USA. The data in the E-poster show that a single injection of [212]Pb-NNV003, or Alpha37, is safe and effective for the treatment of CD37-positive chronic lymphocytic

Mathematical discovery could shed light on secrets of the Universe

[How can Einsteins theory of gravity be unified with quantum mechanics It cant Einstein himself thought But this is a challenge that could give us deep insights into phenomena such as black holes and the birth of the universe Now a new article in Nature Communications written by researchers from Chalmers University of Technology Sweden and MIT USA presents results that cast new light on important challenges in understanding quantum gravity] How can Einstein's theory of gravity be unified with quantum mechanics? It is a challenge that could give us deep insights into phenomena such as

Targovax ASA: Poster presentation at the AACR Annual Meeting

Oslo, Norway, 9 March 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that an abstract has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting.The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated with efficient viral gene expression and strong, sustained activation of immune-related genes, which may be targets for future

Clas Ohlson nine-month report 2021/22

Growth and improved earningsThird quarter quarter – 1 November to 31 January · Sales increased by 7% to 2,831 MSEK (2,635), organic growth up 5% and up 5% in comparable units · Online sales increased by 14% to 329 MSEK (288) · Operating profit amounted to 378 MSEK (358). Excluding the effect of IFRS 16, operating profit totalled 359 MSEK (342) · The operating margin was 13.3% (13.6). Excluding the effect of IFRS 16, the operating margin was 12.7% (13.0) · Net debt/EBITDA excluding the effect of IFRS 16 (12 months) amounted to-1.1 times (-1.2) · Profit after tax

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection) In the key secondary endpoint, efanesoctocog alfa demonstrated superiority in prevention of bleeding episodes, showing a statistically significant and clinically meaningful reduction in annualised bleeding rate compared to prior factor VIII prophylaxis therapy Efanesoctocog alfa is a novel and investigational factor VIII therapy designed to provide near-normal factor activity levels for the majority of the week in a once-weekly

Transactions in connection with share buy-back programme

On 3 March 2022, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). The share buy-back programme is expected to be realised over a 12-month period, starting from 4 March 2022. Under the share buy-back programme, H+H may repurchase shares up to a maximum amount of DKK 150 million. Please refer

Key data demonstrating the potential of Hansa Biopharma’s imlifidase to significantly alter course of anti-GBM disease published in JASN

· Results of an investigator-initiated open-label Phase 2 study of imlifidase in patients with anti-glomerular basement membrane (anti-GBM) disease published in leading nephrology publication Journal of the American Society of Nephrology (JASN).1 · Imlifidase rapidly and completely reduced pathogenic anti-GBM antibody levels to below reference range. · At six months 67% of the included patients had functioning kidneys versus 18% in a historical control cohort. · The publication recognises the study’s significance in autoimmune diseases as it suggests that deactivation of

DSRT: Exercise of employee share options and share capital increase

ISSUER DESERT CONTROL AS Sandnes, Norway, 8 March 2022: Participants in Desert Control AS' ("DesertControl" or the "Company") share option incentive program have on 8 March 2022exercised a total of 375,040 options at a strike price of NOK 0.003. Each optiongives a right to subscribe one share in the Company.Following the exercise, the Board of Directors, pursuant to the authorizationgranted by the Company's Annual General Meeting, has decided to increase theCompany’s share capital by NOK 1,125.12 by issuing 375,040 new shares of parvalue NOK 0.003. Subsequent to the

Össur hf: Board Decisions Following the Annual General Meeting

Announcement no. 17/2022 8 March 2022 Board decisions following the Annual General Meeting Enclosed are the Board decisions following the Annual General Meeting of Össur hf. held today, Tuesday 8 March 2022. Further information Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com, +354 844 4759 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people

Össur hf: Results of the Annual General Meeting

Announcement no. 16/2022 8 March 2022 Results of the Annual General Meeting Enclosed are the results of the Annual General Meeting of Össur hf. held today, Tuesday 8 March 2022.   Further information Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com, +354 844 4759 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people live a Life Without

There are no items matching the current filter
There are no more items matching the current filter
Back to top